Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Exelixis, Inc.

Exelixis, Inc. (EXEL) Stock Overview

Explore Exelixis, Inc.’s financial performance, market position, analyst ratings, and future outlook.

EXEL●NASDAQ
HealthcareBiotechnology
$56.43
$1.37(2.49%)
U.S. Market is Open · 14:14

Exelixis, Inc. (EXEL)

Meyka AI Score

Z

Key Financials

Market Cap14.1B
P/E Ratio17.94
EPS (TTM)$3.34
ROE0.40%
Fundamental Analysis

AI Price Forecasts

1 Month$46.61
3 Months$46.56
1 Year Target$56.19

EXEL Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Exelixis, Inc. (NASDAQ: EXEL) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of A, Exelixis, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of EXEL on the NASDAQ shows an RSI of 54.25, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $56.19 for the NASDAQ listing.

Key metrics behind Exelixis, Inc.'s NASDAQ-traded stock include a P/E ratio of 17.94 and a market capitalization of 14.1B. Combined with our AI analysis, these give both institutional and retail investors a clear view of EXEL on the NASDAQ.

Price Performance (NASDAQ: EXEL)

1-Day Change
1.71%
5-Day Change
2.004%
1-Month Change
0.85%
3-Month Change
26.78%
6-Month Change
31.30%
Year-to-Date (YTD) Change
27.77%
1-Year Change
52.13%
3-Year Change
176.27%
5-Year Change
233.53%
All-Time (Max) Change
279.66%

Contact Information

https://www.exelixis.com
650 837 7000
1851 Harbor Bay Parkway, Alameda, CA, 94502

Company Facts

10,770 Employees
IPO DateApr 17, 2000
CountryUS
Actively Trading

Frequently Asked Questions